Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Company Overview - Corbus Pharmaceuticals Holdings, Inc. is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches targeting well-understood biological pathways [2] - The company's pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a CB1 receptor inverse agonist for obesity treatment [2] Upcoming Events - Yuval Cohen, Ph.D., CEO of Corbus, will participate in the Guggenheim SMID Cap Biotech Conference on February 5-6, 2025, in New York, NY, including an analyst-led fireside discussion and one-on-one investor meetings [1][2] - The presentation is scheduled for February 5, 2025, at 2:30 PM [2]